tradingkey.logo


tradingkey.logo


Trinity Biotech PLC

TRIB
0.575USD
-0.039-6.28%
終倀 03/30, 16:00ET15分遅れの株䟡
4.77M時䟡総額
損倱額盎近12ヶ月PER


Trinity Biotech PLC

0.575
-0.039-6.28%

詳现情報 Trinity Biotech PLC 䌁業名

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Trinity Biotech PLCの䌁業情報


䌁業コヌドTRIB
䌚瀟名Trinity Biotech PLC
䞊堎日Oct 21, 1992
最高経営責任者「CEO」Gillard (John)
埓業員数- -
蚌刞皮類Depository Receipt
決算期末Oct 21
本瀟所圚地Ida Business Park, Bray, Co Wicklow
郜垂DUBLIN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Ireland
郵䟿番号18
電話番号01135312955111
りェブサむトhttps://www.trinitybiotech.com/
䌁業コヌドTRIB
䞊堎日Oct 21, 1992
最高経営責任者「CEO」Gillard (John)

Trinity Biotech PLCの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--

収益内蚳

通貚: USD曎新時刻: Tue, Jan 6
通貚: USD曎新時刻: Tue, Jan 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
事業別USD
䌚瀟名
収益
比率
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
地域別USD
䌚瀟名
収益
比率
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
事業別
地域別
事業別USD
䌚瀟名
収益
比率
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%

株䞻

曎新時刻: Thu, Mar 19
曎新時刻: Thu, Mar 19
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
MiCo IVD Holdings, LLC
11.96%
Novus Diagnostics Ltd
5.99%
Hunter Associates Investment Management LLC
2.81%
Williams & Novak Wealth Management, LLC
0.50%
Two Sigma Investments, LP
0.18%
他の
78.56%
株䞻統蚈
株䞻統蚈
比率
MiCo IVD Holdings, LLC
11.96%
Novus Diagnostics Ltd
5.99%
Hunter Associates Investment Management LLC
2.81%
Williams & Novak Wealth Management, LLC
0.50%
Two Sigma Investments, LP
0.18%
他の
78.56%
皮類
株䞻統蚈
比率
Corporation
17.95%
Investment Advisor
4.01%
Hedge Fund
0.29%
Research Firm
0.14%
Investment Advisor/Hedge Fund
0.09%
他の
77.52%

機関投資家保有株


曎新時刻: Thu, Jan 1
曎新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
52
2.85M
61.97%
+361.31K
2025Q3
51
972.36K
12.90%
+718.71K
2025Q2
50
3.17M
16.99%
-2.03M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
MiCo IVD Holdings, LLC
2.24M
60.6%
+1.79M
+400.00%
Dec 08, 2025
Hunter Associates Investment Management LLC
487.11K
13.19%
+399.53K
+456.18%
Sep 30, 2025
Williams & Novak Wealth Management, LLC
12.00K
0.32%
+7.60K
+172.73%
Sep 30, 2025
Two Sigma Investments, LP
36.23K
0.98%
+33.22K
+1101.76%
Sep 30, 2025
Moss Adams Wealth Advisors LLC
25.67K
0.69%
+20.53K
+400.02%
Sep 30, 2025
Inspirion Wealth Advisors, LLC
10.00K
0.27%
+8.00K
+400.00%
Sep 30, 2025
Cambridge Investment Research Advisors, Inc.
22.28K
0.6%
+17.82K
+400.00%
Sep 30, 2025
Raymond James & Associates, Inc.
20.32K
0.55%
+15.25K
+300.77%
Sep 30, 2025
Renaissance Technologies LLC
171.36K
4.64%
+159.97K
+1404.10%
Sep 30, 2025
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
日付
配圓萜ち日
皮類
比率
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
KeyAI
î™